Legend Biotech’s Post

#Article now available! Achieving flexibility & scalability in #celltherapymanufacturing through optimized #cellisolation & activation In this article, Eugene Kang (Senior Product Manager, Thermo Fisher Scientific) discusses flexible solutions that can support both #autologous and #allogeneic processes. Read this #article to learn about: • Optimizing drug efficacy and cost • Automating cell isolation and activation • Improving upon current cell therapy manufacturing methods • Scaling up with automated instrumentation Read below:

Launching a market-first continuous bioprocessing platform took time, perseverance, and a lot of 'breaking down barriers', a CellRev company value. We couldn't be prouder to finally see Livit ACE available on the market. A platform capable of speeding up development times, reducing cost per dose, and enabling mass-market access to the next evolution of cell therapies. Our team reflected on some of the major milestones in the journey. _______________________________ Need a more efficient adherent cell expansion platform? Contact the team to discuss your requirements on [email protected] or download the brochure here - https://lnkd.in/eCMb3U3z Getinge #celltherapy #biomanufacturing #cellculture #bioprocessing

this will be an excellent discussion at ASGCT: Overcoming Challenges in Translating Research to Scalable Manufacturing!

🔬 Two months post-Advanced Therapies Week 2024, and the insights from Xavier de Mollerat du Jeu, Gianluca Pettiti, and Fred (Federico) Parietti's workshop continue to resonate. Their discussion on enhancing clinical outcomes through innovative manufacturing processes marked a pivotal moment for cell therapy. Let's revisit the groundbreaking solutions introduced and how they're shaping the future. #AdvancedTherapiesWeek #CellTherapyInnovation #ThermoFisherScientific"

Achieving optimal #cellharvest is important across the development continuum and at every phase of scale-up. While unique challenges exist for all cell therapies, optimizing harvest conditions for #allogeneic cell therapies comes with unique considerations to achieve the manufacturing scales required for these promising innovations. Enabling the yields, reproducibility, and larger production volumes necessary to support allogeneic applications will be key to addressing some of the core challenges that have limited their commercialization potential in the past. For many applications, cutting-edge centrifugation technologies can help achieve optimization, affording developers and manufacturers a low-shear, high-yield cell harvest that is tightly controlled and highly reproducible. #celltherapy #celltherapies By Jacob Andrews, CARR Biosystems

Thank you Cell & Gene for having us on! If you want to hear more about our CEO Nicholas Siciliano's POV on the current state of cell therapy manufacturing and the next evolution of #automation, check out the webinar link below.

In this #InFocus we review the current methodologies for cell expansion and reveal solutions to overcome common challenges when manufacturing cell therapies at scale. Visit the feature >>> https://bit.ly/48r4lmt

Yesterday, I attended a webinar delivered by Kim Watanabe, Michele Duggan, and Mindy Sadik from Thermo Fisher Scientific, which focused on positioning early cell therapy programs for clinical success. The session provided insights into mitigating risks and ensuring GMP readiness in this rapidly evolving field. Key takeaways from the webinar included: 1. Strategic Planning: It is essential to 'begin with the end in mind', strategically planning every step to mitigate risks and ensure GMP readiness. 2. Technological Integration: Streamlining workflows through the integration of advanced technologies can significantly enhance efficiency. 3. Operational Optimisation: Efficiency can be optimized through various means, such as automation, digitisation, and scalable platforms. 4. Analytical Rigor: Analytical assays play a critical role and should be qualifiable, transferable, and adhere to appropriate standards and controls. 5. Collaborative Partnerships: Collaborating with CRO/CDMO partners simplifies the cell therapy value chain and enhances patient-centricity. Reflecting on the insights shared, it's evident that many of these principles resonate with our approach at adthera bio. We've embraced a digital-first mindset and integrated a diverse range of automated platforms, including closed systems. Our goal at adthera bio is to bring novel C&GTs to the market with a highly personalised approach, ensuring a seamless journey from the client to the patient. #cellandgenetherapy #atmps #digitalfirst #cell&genetherapyinsights #biotechnology

The future of advanced therapies is here, and it's all about decentralization! 🌍✨ Dive into our latest article, based on an engaging discussion from panel 5 at #ATW24 with Phacilitate, featuring industry experts Sean Bartholomew of Germfree and Grayson Heller of cGMPnow. Learn the critical strategies for decentralized manufacturing models, including a copy-paste approach for identical and cloned processes across multiple locations. 🙌 Don't miss out on these insights that are shaping the future of cell therapy manufacturing! ⬇️ #AdvancedTherapies #CellTherapy #DecentralizedManufacturing #Innovation #Biotech